Cardiovascular risk factors in patients with prostate cancer of a cardio-oncology unit
DOI:
https://doi.org/10.24054/cbs.v2i2.2927Keywords:
hypertension, obesity, smoking, prostate cancerAbstract
Background: Cardiovascular disease has become the main cause of mortality in prostate cancer. Diagnosing and management of risk factors in these patients represent an opportunity to optimize survival outcomes. Objective: to evaluate the presence of cardiovascular risk factors in prostate cancer with and without bone metastasis from a Cardio-Oncology Unit. Method: observational, descriptive study on weight, hypertension, diabetes, smoking, and dyslipidemia. Results: 420 patients with prostate cancer were analyzed, and seventy-four had bone metastasis. The average age was 70 years. The most frequent risk factor was overweight (44.3%), hypertension (34.5%); diabetes 9.5%, smoking (16%) and Dyslipidemia (19.8%). Hypertension and diabetes were the most common in prostate cancer and bone metastasis compared with non-metastatic. A significant association was found between smoking and dyslipidemia; patients with metastasis smoke less but have greater hypercholesterolemia. The presence of three or more risk factors predominated in metastatic patients (31.1%) than in non-metastatic (15.9%) with a significant difference (p<0.001). Conclusion: Subjects with prostate cancer at the time of diagnosis are more frequently overweight and have hypertension. Patients with prostate cancer and bone metastasis more regularly have three or more factors compared with non-metastatic. The at-risk population should continue cardiovascular control in a Cardio-Oncology unit.
Downloads
References
Globocan 2018 [Internet]. Lyon, France: International Agency for Research on Cancer. c2013- [cited 2018 Sep 23]. Available from: http://globocan.iarc.fr
Okwuosa TM, Morgans A, Rhee JW, Reding KW, Maliski S, Plana JC, et al. American Heart Association Cardio-Oncology Subcommittee of the Council on Clinical Cardiology and the Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on Cardiovascular Radiology and Intervention. Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement from the American Heart Association. Circ Genom Precis Med. 2021 Jun;14(3): e000082. DOI: https://doi.org/10.1161/HCG.0000000000000082
Zaorsky NG, Churilla TM, Egleston BL, Fisher SG, Ridge JA, Horwitz EM, et al. Causes of death among cancer patients. Ann Oncol. 2017; 1;28(2):400-407. DOI: https://doi.org/10.1093/annonc/mdw604
Liu D, Ma Z, Yang J, Zhao M, Ao H, Zheng X, et al. Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study. Aging (Albany NY). 2019; 27;11(18):7948-7960. DOI: https://doi.org/10.18632/aging.102301
Swaby J, Aggarwal A, Batra A, Jain A, Seth L, Stabellini N, et al. Association of Androgen Deprivation Therapy with Metabolic Disease in Prostate Cancer Patients: An Updated Meta-Analysis, Clinical Genitourinary Cancer, 2023; 21 (3): e182-9. DOI: https://doi.org/10.1016/j.clgc.2022.12.006
Sun L, Parikh RB, Hubbard RA, et al. Assessment and Management of Cardiovascular Risk Factors Among US Veterans with Prostate Cancer. JAMA Netw Open. 2021;4(2): e210070. DOI: https://doi.org/10.1001/jamanetworkopen.2021.0070
Suárez-Carmona W, Sánchez-Oliver A. Indice de Masa Corporal: ventajas y desventajas de su uso en la obesidad. Relación con la fuerza y la actividad física. Nutr Clin Med 2018; 12 (3): 128-139.
Rubio-Guerra AF. Nuevas guías del American College of Cardiology/American Heart Association Hypertension para el tratamiento de la hipertensión. ¿Un salto en la dirección correcta? Med Int Mex. 2018;34(2):299-303.
Alfaro T. Situación Epidemiológica en Chile de las ENT y sus factores de riesgo. Unidad de Estudios y VENT, Departamento de Epidemiologia, DIPLAS Taller Regional de Vigilancia Epidemiológica de Enfermedades No Transmisibles. Ministerio de Salud, Gobierno de Chile. Valparaíso, 1 de septiembre 2011.
Caro Dougnac D. Impacto económico de las enfermedades crónicas. Santiago de Chile: Universidad de Chile; 2014.
Gómez-Portilla A, Martínez de Lecea C, Cendoya I, Olabarría I, Martín E, Magrach L. et al. Prevalencia y tratamiento de la patología oncológica en el anciano: El reto que se avecina. Rev. esp. enferm. dig. 2008; 100(11): 706-715. DOI: https://doi.org/10.4321/S1130-01082008001100007
Kim KB, Shin YA. Males with Obesity and Overweight. J Obes Metab Syndr. 2020; 29 (1): 18-25. DOI: https://doi.org/10.7570/jomes20008
Sánchez C, Ibáñez C, Klaassen J. Obesidad y cáncer: la tormenta perfecta. Rev. Méd. Chile. 2014;142(2): 211-221. DOI: https://doi.org/10.4067/S0034-98872014000200010
Linden-Castro E, Pelayo-Nieto M, Alias-Melgar A, Perez-Grovas D, Ramírez-Pedraza J, Morales-Covarrubias J, et al. ¿Es la obesidad un factor predictor de agresividad en cáncer de próstata?, Rev Mex Urol. 2014; 74 (5): 275-280. DOI: https://doi.org/10.1016/j.uromx.2014.09.005
Organización Mundial de la Salud. Información general sobre la Hipertensión en el mundo. Ginebra. Setiembre 2013.
Stocks T, Hergens MP, Englund A, Ye W, Stattin P. Blood pressure, body size and prostate cancer risk in the Swedish Construction Workers cohort. Int J Cancer. 2010;127(7):1660-8. DOI: https://doi.org/10.1002/ijc.25171
Ruiz-Mori E. Riesgo y Prevención Cardiovascular. 1° Edic. Lima. Unigraph. 2014
Wallner LP, Wang R, Jacobsen SJ, Haque R. Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies. Cancer Epidemiol Biomarkers Prev. 2013;22(2):313-6. DOI: https://doi.org/10.1158/1055-9965.EPI-12-1137
Siltari A, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PLoS ONE 2020;15(6): e0234269. DOI: https://doi.org/10.1371/journal.pone.0234269
Jiménez-Mendoza E, Vázquez-Salas RA, Barrientos-Gutierrez T, Reynales-Shigematsu L, Labra-Salgado I, Manzanilla-García H, et al. Smoking and prostate cancer: a life course analysis. BMC Cancer. 2018; 18: 160. DOI: https://doi.org/10.1186/s12885-018-4065-7
Hager MH, Solomon KR, Freeman MR. The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care. 2006;9(4):379-85. DOI: https://doi.org/10.1097/01.mco.0000232896.66791.62
Jamnagerwalla J, Howard LE, Allott EH, Vidal AC, Moreira DM, Castro-Santamaria R, et al. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis. 2018 ;21(2):252-259. DOI: https://doi.org/10.1038/s41391-017-0030-9
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Revista Ciencias Básicas en Salud
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
